Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Claudepierre

Showing results (51-60 of 154) with videos related to

Pageof 16
Sort By:
The Journal of Rheumatology|January 6, 2004
Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or COwonayo Oniankitan, Christophe Duvoux, Dominique Challine, et al.
The Journal of Rheumatology|January 6, 2006
Estimation of the Bath Ankylosing Spondylitis Disease Activity Index cutoff for perceived symptom relief in patients with spondyloarthropathiesJean-David Cohen, Patrick Cunin, Valérie Farrenq, et al.
International Journal of Rheumatic Diseases|April 17, 2019
Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohortPascal Claudepierre, Filip Van den Bosch, Piercarlo Sarzi-Puttini, et al.
Arthritis Research & Therapy|January 17, 2019
Association between IL23R and ERAP1 polymorphisms and sacroiliac or spinal MRI inflammation in spondyloarthritis: DESIR cohort dataAdeline Ruyssen-Witrand, Cécile Luxembourger, Alain Cantagrel, et al.
The Journal of Rheumatology|April 17, 2008
Cutaneous granulomas during infliximab therapy for spondyloarthropathyAndra Economu Dubosc, Anne-Marie Perroud, Martine Bagot, et al.
Expert Opinion on Biological Therapy|May 27, 2026
Shared challenges in the management of difficult-to-treat chronic inflammatory diseases: expert perspectivesLaure Gossec, Hubert Marotte, Ziad Reguiai, et al.
Joint Bone Spine|June 18, 2011
Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAICécile Gaujoux-Viala, Gaël Mouterde, Athan Baillet, et al.
Arthritis Care & Research|September 16, 2020
Inflammation of the Sacroiliac Joints and Spine and Structural Changes on Magnetic Resonance Imaging in Axial Spondyloarthritis: Five-Year Data From the DESIR CohortAlexandre Sepriano, Sofia Ramiro, Robert Landewé, et al.
Journal of Medical Economics|April 12, 2016
Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in FranceFrancis Fagnani, Thao Pham, Pascal Claudepierre, et al.
Journal of the American Academy of Dermatology|November 17, 2025
Risk of immunogenicity during infliximab therapy in hidradenitis suppurativa compared with other chronic inflammatory diseases: A retrospective monocentric cohortCamille Barral, Ramatoulaye Ndiaye, Christina Bergqvist, et al.
Pageof 16

Showing results (51-60 of 154) with videos related to

Sort By:
Pageof 16
The Journal of Rheumatology|January 6, 2004
Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or COwonayo Oniankitan, Christophe Duvoux, Dominique Challine, et al.
The Journal of Rheumatology|January 6, 2006
Estimation of the Bath Ankylosing Spondylitis Disease Activity Index cutoff for perceived symptom relief in patients with spondyloarthropathiesJean-David Cohen, Patrick Cunin, Valérie Farrenq, et al.
International Journal of Rheumatic Diseases|April 17, 2019
Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohortPascal Claudepierre, Filip Van den Bosch, Piercarlo Sarzi-Puttini, et al.
Arthritis Research & Therapy|January 17, 2019
Association between IL23R and ERAP1 polymorphisms and sacroiliac or spinal MRI inflammation in spondyloarthritis: DESIR cohort dataAdeline Ruyssen-Witrand, Cécile Luxembourger, Alain Cantagrel, et al.
The Journal of Rheumatology|April 17, 2008
Cutaneous granulomas during infliximab therapy for spondyloarthropathyAndra Economu Dubosc, Anne-Marie Perroud, Martine Bagot, et al.
Expert Opinion on Biological Therapy|May 27, 2026
Shared challenges in the management of difficult-to-treat chronic inflammatory diseases: expert perspectivesLaure Gossec, Hubert Marotte, Ziad Reguiai, et al.
Joint Bone Spine|June 18, 2011
Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAICécile Gaujoux-Viala, Gaël Mouterde, Athan Baillet, et al.
Arthritis Care & Research|September 16, 2020
Inflammation of the Sacroiliac Joints and Spine and Structural Changes on Magnetic Resonance Imaging in Axial Spondyloarthritis: Five-Year Data From the DESIR CohortAlexandre Sepriano, Sofia Ramiro, Robert Landewé, et al.
Journal of Medical Economics|April 12, 2016
Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in FranceFrancis Fagnani, Thao Pham, Pascal Claudepierre, et al.
Journal of the American Academy of Dermatology|November 17, 2025
Risk of immunogenicity during infliximab therapy in hidradenitis suppurativa compared with other chronic inflammatory diseases: A retrospective monocentric cohortCamille Barral, Ramatoulaye Ndiaye, Christina Bergqvist, et al.
Pageof 16